The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

A new study from UCLA Health suggests COVID-19 vaccines may protect patients from severe kidney damage. The study found ...

Pfizer and other drug companies have met with the Trump administration to discuss lowering U.S. drug prices but no ...

Pfizer Inc. (NYSE:PFE) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Analyst Asad Haider of Goldman ...

Pfizer offers a high 7.4% dividend yield and trades at low valuation multiples. Click here to read more about PFE stock and ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...

The rally in the sector this year outpaces the 17% gain in China’s tech stocks that was driven by the release of DeepSeek’s ...

China's biotechnology stocks have experienced a significant rally, outperforming AI, with a 60% surge since January due to ...

Despite recent declines, we believe Pfizer stock is a compelling buy right now, with its current price of around $23 likely ...

While Pfizer said in its petition for mass tort designation that it expected many of the dismissed plaintiffs to refile their ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

Pfizer halted its oral obesity drug, danuglipron, in April 2025 due to liver injury concerns, a major pipeline setback. Find out why PFE stock is a Hold.